Clinical Trial Update: Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating pegylated alfa interferon, sunitinib, and tarceva in patients with metastatic renal cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Pegylated Alfa Interferon (pegylated interferon alfa)
• Sunitinib (sunitinib)
• Tarceva (erlotinib)

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Carcinoma, Renal Cell | Phase 1, Phase 2 | Status: TERMINATED